Artera Gets FDA Okay for Prostate Cancer AI

Artera gets FDA okay for prostate cancer AI

A newly approved AI from Artera can guide treatment and predict prognosis in people diagnosed with localised prostate cancer

FDA grants De Novo authorization for first AI-powered prostate cancer prognostic tool

ArteraAI Prostate advances prostate cancer care with FDA authorization, offering AI-driven insights for personalized treatment and improved diagnostic efficiency.

Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care

Novel risk stratification tool advances the frontier of precision oncology by providing access to insights informing critical on-the-ground treatment decisionsSAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence ... L'articolo Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care è un contenuto originale di 01net.

FDA grants de novo authorization to ArteraAI Prostate

The ArteraAI test is now the first and only AI-powered tool to be authorized to prognosticate long-term outcomes in patients with localized prostate cancer.